The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term symptom burden and orodental health of oropharyngeal cancer (OPC) survivors following treatment with chemoradiotherapy (CRT) or sequential therapy (ST).
Sewanti Atul Limaye
No relevant relationships to disclose
Robert I. Haddad
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim
Ann Partridge
No relevant relationships to disclose
Anne M. O'Neill
No relevant relationships to disclose
Andrea Radossi
No relevant relationships to disclose
Aditya V. Shreenivas
No relevant relationships to disclose
David Lorente
No relevant relationships to disclose
Glenn J. Hanna
No relevant relationships to disclose
Stephen T. Sonis
Employment or Leadership Position - Biomodels
Consultant or Advisory Role - ActoGeniX; Alder Biopharmaceuticals; BioAlliance Pharma; CAP Pharma; Galera Therapeutics; Pfizer; Piramal; Polymedix; Synedgen
Lawrence N. Shulman
No relevant relationships to disclose
Marshall R. Posner
No relevant relationships to disclose
Jochen H. Lorch
No relevant relationships to disclose